470.11MMarket Cap-2.32P/E (TTM)
11.730High10.800Low1.23MVolume11.010Open11.100Pre Close13.79MTurnover3.46%Turnover RatioLossP/E (Static)40.56MShares72.37052wk High0.82P/B410.58MFloat Cap9.77552wk Low--Dividend TTM35.43MShs Float88.800Historical High--Div YieldTTM8.38%Amplitude9.775Historical Low11.252Avg Price1Lot Size
Keros Therapeutics Stock Forum
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
Combining pure anti-Myostatin antibodies with Semaglutide was marginally effective in NHPs in preventing muscle loss. I believe that for that reason, $Scholar Rock (SRRK.US)$ and probably also $Biohaven (BHVN.US)$ are likely to disappoint.
Additionally blocking other ligands like Activin A dramatically improves body composition. That is what $Eli Lilly and Co (LLY.US)$ , $Keros Therapeutics (KROS.US)$ ...
No comment yet